Abstract: Methods and compositions for the use of CRISPR/Cas9 technology for treating RP1 mutation-associated autosomal dominant Retinitis Pigmentosa (adRP).

Abstract: A method and system for managing a therapeutic substance regimen including: receiving therapeutic substance information from a user; receiving information regarding a regimen; providing interaction information based on the therapeutic substance information; receiving an ascertainment of adherence to the regimen at a set of time points; generating an adherence metric based upon the ascertainment and the set of time points; providing a reward to the user based on the adherence metric; and providing an automated notification to the user based upon at least one of the ascertainment, the adherence metric, and the reward. The method can further comprise providing an advertisement to the user based on one of the therapeutic substance information and the regimen, generating a comparison of the adherence metric for the user to the adherence metric for a second user, and generating an automated refill or renewal request based upon the therapeutic substance information and the regimen.